Director Michelle Renee Griffin sold 52,084 shares of ADPT at $20.18 (-1.1% from 52-week high) per pre-arranged 10b5-1 plan; retains 15,625 shares.
Director Michelle Renee Griffin executed a scheduled sale of 52,084 shares at $20.18 under a pre-arranged 10b5-1 trading plan adopted on 2025-11-07, reducing her non-derivative holdings from 67,709 shares to 15,625 shares. The sale occurred as the stock trades near its 52-week high of $21.64 (-1.1%) and amid significant recent momentum (+41.2% over 30 days, +54.2% over 90 days), yet the transaction was pre-planned rather than discretionary. Adaptive Biotechnologies remains unprofitable on a full-year basis (net income: $-20,033,000.00), though revenue growth has accelerated sharply at +54.8% year-over-year, creating a growth-at-loss profile. The timing coincides with the stock's elevated valuation relative to recent trading ranges, though the 10b5-1 framework precludes any inference about insider market timing or conviction.